|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors显示文摘 | Gandhi L Bahleda R Tolaney SM | 2014 | J Clin Oncol2014，32，2： | 1 |
| 2 | Adjuvant paelitaxel and Trastuzumab for node-negative, HER2-positive breast cancer显示文摘 | Tolaney SM Barry WT Dang CT | 2015 | N Engl J Med2015，372，2： | 1 |
| 3 | Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer显示文摘 | Tolaney SM Barry WT Dang CT | 2015 | N Engl J Med2015，372，2： | 1 |
| 4 | Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors 显示文摘 | Gandhi L Bahleda R Tolaney SM | 2014 | J Clin Oncol2014，32，2： | 1 |
| 5 | MNARCHI: Results from a phase I1 study of abemaciclib,a CDK4 and CI)K6 inhibitor,as monotherapy,in patients with HR+/ tIER2- breasl cancer,after chemotherapy for advanceddisease显示文摘 | Diekler MN Tolaney SM Rugo HS et a | 2016 | J Clin Oncol2016，，： | 1 |
| 6 | Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer 显示文摘 | Tolaney SM Barry WT Dang CT | 2015 | N Engl J Med2015，372，2： | 1 |
| 7 | Adjuvant paclitaxel and trastuzumab for node-negative,HER2-positive breast cancer显示文摘 | Tolaney SM Barry WT Dang CT | 2015 | N Engl J Med2015，372，2： | 1 |
| 8 | Adjuvant paclitaxel and trastuzumab for node-negative, HER-2 positive breast cancer 显示文摘 | Tolaney SM Barry WT Dang CT | 2015 | N EnglJ Med2015，372，2： | 1 |
| 9 | A phase I trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer显示文摘 | Liu JF Tolaney SM Birrer M | 2013 | Eur J Cancer2013，49，14： | 1 |
| 10 | Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer显示文摘 | Tolaney SM Barry WT Dang CT | 2015 | N Engl J Med2015，372，2： | 1 |
| 11 | A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) incombination with the anti-angiogenic cediranib (AZD2171)in recurrent epithelial ovarian or triple-negative breast cancer显示文摘 | Liu JF Tolaney SM Birrer M | 2013 | Eur J Cancer2013，49，14： | 1 |
| 12 | A Phase 1 trial of the poly (ADP-ribose) polymerase inhibitor olaparib ( AZD2281 ) in combination with the anti-angiogenic cediranib ( AZD2171 ) in recurrent epithelial ovarian or triple-negative breast cancer 显示文摘 | LIU JF TOLANEY SM BIRRER M | 2013 | Eur J Cancer2013，49，14： | 1 |
| 13 | Adjuvant paclitaxel and trastuzumab for node-negative,HER2-positive breast cancer显示文摘 | Tolaney SM Barry WT Dang CT | 2015 | N Engl J Med2015，372，2： | 1 |
| 14 | Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer 显示文摘 | Tolaney SM Barry WT Dang CT | 2015 | N Engl J Med2015，372，2： | 1 |
| 15 | Adjuvant paclitaxel and trastuzumab for node - negative, HER2 - positive breast cancer 显示文摘 | Tolaney SM Barry WT Dang CT | 2015 | NEnglJMed2015，372，2： | 1 |
| 16 | Lymphopenia associated with adjuvant anthracycline/taxane regimens 显示文摘 | Tolaney SM Najita J Wincr EP | 2008 | Clin Breast Cancer2008，8，： | 1 |
| 17 | Neoadjuvant bevacizum-ab : surgical complications of mastectomy with and without reconstruction显示文摘 | Kansal KJ Dominici LS Tolaney SM’ | 2013 | Breast Cancer Res Treat2013，141，2： | 1 |
| 18 | A phase 1 trial of the poly (ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD217) in recurrent epithelial ovarian or triple-negative breast cancer 显示文摘 | Liu JF Tolaney SM Birrer M | 2013 | Eur J Cancer2013，49，14： | 1 |
| 19 | A Phase 1 trial of the poly(ADP-ribose)polymerase inhibitor olaparib(AZD2281)in combination with the anti-angiogenic cediranib(AZD2171)in recurrent epithelial ovarian or triple-negative breast cancer显示文摘 | LIU JF TOLANEY SM BIRRER M | 2013 | Eur J Cancer2013，49，14： | 1 |
| 20 | Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer显示文摘 | Tolaney SM Barry WT Dang CT | 2015 | N Engl J Med2015，372，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员